PhaRmacodynamic Effect of Therapy With PraSugrel or TicagrElor in Acute Coronary Syndrome paTients With Diabetes Mellitus (RESET 2D)

This study is not yet open for participant recruitment.

Verified April 2013 by University of Roma La Sapienza

Sponsor:

Information provided by (Responsible Party):

Gennaro Sardella, University of Roma La Sapienza

ClinicalTrials.gov Identifier:

NCT01531114

First received: February 7, 2012

Last updated: April 19, 2013

Last verified: April 2013

History of Changes

Purpose

Dual antiplatelet therapy with aspirin and Clopidogrel for at least one year is essential in patients following an acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI) and drug eluting stent(s) implantation. Current guidelines recommend prasugrel and ticagrelor in patients with ACS undergoing primary percutaneous coronary intervention (PPCI). We sought to investigate the non-inferiority antiplatelet effect in terms of level platelet reactivity (< 240 PRU) of loading dose of prasugrel (60 mg) versus loading dose of Ticagrelor (180 mg) in patients undergoing PPCI at 6 hours from the administration of the drug (primary end-point). Secondary end-points will be in hospital NACE (cardiovascular death, myocardial infarction, stroke and bleedings according to the TIMI criteria), stent thrombosis in overall population. All consecutive diabetic patients with acute coronary syndrome (ACS) undergoing PPCI with stent implantation will be considered for PR assessment at 2-6-12 h after the drug loading dose administration. All patients must will be naïve for platelet P2Y12 receptor inhibition therapy.

Condition	Intervention	Phase
Acute Coronary Syndrome	Drug: ticagrelor Drug: prasugrel	Phase 3

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Pharmacokinetics/Dynamics Study Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	PhaRmacodynamic Effect of Therapy With PraSugrel or TicagrElor in Acute Coronary Syndrome paTients With Diabetes Mellitus.RESET 2D Trial

Resource links provided by NLM:

MedlinePlus related topics: Diabetes

Drug Information available for: Ticagrelor

U.S. FDA Resources

Further study details as provided by University of Roma La Sapienza:

Primary Outcome Measures:

The non-inferiority antiplatelet effect in terms of level platelet reactivity (< 240 PRU) of loading dose of prasugrel (60 mg) versus loading dose of Ticagrelor (180 mg) in patients undergoing PPCI at 6 hours from the administration of the drug. [ Time Frame: 6 hours ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Bleeding (major, minor, or minimal according to the TIMI study criteria) [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
Bleeding (major, minor, or minimal according to the TIMI study criteria)

Other Outcome Measures:

major adverse cardiac events (cardiovascular death, myocardial infarction, stroke, stent thrombosis) [ Time Frame: in hospital ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	30
Study Start Date:	May 2013
Estimated Study Completion Date:	August 2013
Estimated Primary Completion Date:	August 2013 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: Prasugrel loading dose Patients will be randomized to this arm to receive loading dose of prasugrel	Drug: ticagrelor Patients will be randomized to this arm to receive loading dose of ticagrelor Drug: prasugrel Patients will be randomized to this arm to receive loading dose of prasugrel
No Intervention: ticagrelor loading dose Patients will be randomized to this arm to receive loading dose of ticagrelor

Eligibility

Ages Eligible for Study:	18 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Diabetic patients
acute coronary syndrome
patients underwent to primary PCI
naïve for platelet P2Y12 receptor inhibition therapy

Exclusion Criteria:

history of bleeding diathesis
chronic oral anticoagulation treatment
contraindications to antiplatelet therapy
PCI or coronary artery bypass grafting (CABG) < 3 months
hemodynamic instability
platelet count < 100,000/μl
hematocrit < 30%
creatinine clearance < 25 ml/min
Patients with a history of stroke
contraindication for prasugrel administration
patients weighing < 60 kg
> 75 years of age.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT01531114

Contacts

Contact: Gennaro Sardella, MD

+390649979035

rino.sardella@uniroma1.it

Locations

Italy
Dept.of Cardiovascular Sciences,Policlinico Umberto I	Recruiting
Rome, Italy, 00161
Contact: Simone Calcagno, MD +390649979044 calcagnosimone@libero.it
Contact: Massimo Mancone, MD +390649979044 massimomancone@gmail.com
Sub-Investigator: Simone Calcagno, MD
Sub-Investigator: Masismo MANCONE, MD
Sub-Investigator: MAURO PENNACCHI, MD

Sponsors and Collaborators

Gennaro Sardella

More Information

No publications provided

Responsible Party:	Gennaro Sardella, Associate Professor in Cardiology, University of Roma La Sapienza
ClinicalTrials.gov Identifier:	NCT01531114 History of Changes
Other Study ID Numbers:	RESET 2D
Study First Received:	February 7, 2012
Last Updated:	April 19, 2013
Health Authority:	Italy: Ethics Committee

Keywords provided by University of Roma La Sapienza:

Diabetes mellitus
antiplatelet effect
prasugrel
ticagrelor
acute coronary syndrome

Additional relevant MeSH terms:

Diabetes Mellitus
Acute Coronary Syndrome
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Angina Pectoris
Vascular Diseases
Chest Pain
Pain

Signs and Symptoms
Prasugrel
Ticagrelor
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 23, 2013

To Top